In addition to the identification of targets specific to hematopoietic cells52, several strategies, including the treatment of tolerogenic anti-IL-2 antibodies and transient depletion of CD4 T cells, were examined for ameliorating GvHD while sustaining the GvL effect of allo-HSCT in patients with hematological malignancies45,53. The gene discussed is IL2; the disease is graft versus host disease.